Both sugar-sweetened beverages and low or non-sugar-sweetened beverages were linked to an increased risk for metabolic ...

Artificially-sweetened and sugary beverages both raised the risk of metabolic dysfunction-associated steatotic liver disease ...

Researchers in Sweden and Finland have created the CORE model, a simple blood test that predicts liver disease risk with striking accuracy. Unlike current methods, it works for the general population ...

The accumulation of fat inside liver cells is known as fatty liver disease. The liver develops fatty deposits through excessive alcohol consumption (alcoholic fatty liver) or obesity, diabetes and ...

Rochester, Minn.-based Mayo Clinic developed an artificial intelligence model using electrocardiogram data that outperformed the current model for ...

Good liver health is important. Nonalcoholic fatty liver disease is common. Diet and exercise are key. Coffee and leafy greens help. Beans, soy, and fatty fish are beneficial. Avoid alcohol and added ...

Hall of Fame quarterback Dan Marino recently revealed that he was diagnosed with metabolic dysfunction-associated steatohepatitis, or MASH. The Miami Dolphins legend said the discovery came years ago ...

SIX. MIAMI DOLPHINS HALL OF FAME QUARTERBACK DAN MARINO REVEALED TODAY HE HAS LIVER DISEASE. HE SPOKE WITH PEOPLE MAGAZINE IN AN INTERVIEW PUBLISHED TODAY ON HIS 64TH BIRTHDAY. MARINO SAYS HE WAS ...

Obesity, type 2 diabetes, and certain lifestyle habits can increase your risk of metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD, formally called nonalcoholic fatty liver ...

Alcohol doesn’t just damage the liver — it locks its cells in a strange “in-between” state that prevents them from healing. Even after someone quits drinking, liver cells often get stuck, unable to ...

Metabolic dysfunction-associated steatotic liver disease (MASLD), formally called nonalcoholic fatty liver disease (NAFLD), is a chronic condition that can lead to liver inflammation, damage, and ...

Roche targets liver disease treatments with acquisition Deal includes $14.50 a share, potential milestone payments up to $6.00 a share Roche flags potential to treat obesity-related conditions The ...